目的 統(tǒng)計(jì)上海交通大學(xué)醫(yī)學(xué)院附屬蘇州九龍醫(yī)院（簡(jiǎn)稱蘇州九龍醫(yī)院）近3年抗腫瘤靶向藥物的使用情況，分析用藥趨勢(shì)，為抗腫瘤靶向藥物的合理使用提供參考。方法 采用限定日劑量（DDD），對(duì)2017—2019年蘇州九龍醫(yī)院抗腫瘤靶向藥物的品種、規(guī)格、銷售數(shù)量、銷售金額、用藥頻度（DDDs）、日均費(fèi)用（DDC）和排序比（B/A）等進(jìn)行統(tǒng)計(jì)分析。結(jié)果 蘇州九龍醫(yī)院近3年抗腫瘤靶向藥物使用數(shù)量和使用金額逐年增長(zhǎng)，奧希替尼在所有抗腫瘤靶向藥物中增長(zhǎng)最為迅速，DDDs已升至第一位。大分子抗體藥物增速較快，DDC也普遍偏高，銷售金額將趕超小分子激酶抑制劑。?？颂婺岬腂/A連續(xù)3年≥2.00，利妥昔單抗的B/A綜合最低。結(jié)論 隨著醫(yī)療政策的傾斜、藥品降價(jià)，抗腫瘤靶向藥物將使更多的患者獲益。

Objective To count the use of anti-tumor targeted drugs in Suzhou Kowloon Hospital in recent 3 years, analyze the trend of drug use, and provide reference for the rational use of anti-tumor targeted drugs. Methods The variety, specification, quantity of sales, amount of sales, frequency of drug use (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A) of anti-tumor targeted drugs of Suzhou Kowloon Hospital from 2017-2019 were analyzed by defined daily dose(DDD). Results In recent 3 years, the quantity and amount of anti-tumor targeted drugs increased year by year. Osimertinib was the fastest growing of all anti-tumor targeted drugs, and DDDs had risen to the first place. The growth rate of macromolecular antibody drugs was fast, and DDC was generally on the high side. The sales amount will catch up with and surpass that of small molecule kinase inhibitors. While B/A of Icotinib was ≥ 2.00 for 3 consecutive years, B/A of rituximab was the lowest. Conclusion With the inclination of medical policy and drug price reduction, more and more patients will benefit from anti-tumor targeted drugs.

R979.1